Rene Russo Net Worth

Rene Russo biography

Dr. Rene Russo serves as Director of the Company. Dr. Russo has served as a member of our board of directors and as our President and Chief Executive Officer since April 2016. Dr. Russo served as our Chief Development Officer from July 2015 until April 2016. Previously, Dr. Russo served in various roles over an 11-year period at Cubist Pharmaceuticals, Inc., a public pharmaceutical development company, focused on the development and commercialization of infectious disease therapeutics, from 2003 until its acquisition by Merck in May 2015, most recently as its Vice President, Global Medical Affairs. From 1999 to 2004, she held roles of increasing responsibility at Bristol-Myers Squibb where she started her industry career as a Postdoctoral Fellow in Industrial Pharmacy Infectious Diseases. Prior to joining the biotechnology industry, Dr. Russo held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital. Dr. Russo received her Pharm.D. and B.S. from Rutgers University. Our board of directors believes that Dr. Russo’s expertise and experience as our President and Chief Executive Officer, her perspective and experience as an executive at public and private pharmaceutical companies and her expertise in clinical development and commercialization of therapeutics targeting infectious diseases, provide her with the qualifications and skills to serve on our board of directors.

What is the salary of Rene Russo?

As the Director of X4 Pharmaceuticals, the total compensation of Rene Russo at X4 Pharmaceuticals is $69,716. There are 10 executives at X4 Pharmaceuticals getting paid more, with Paula Ragan having the highest compensation of $2,497,790.

How old is Rene Russo?

Rene Russo is 45, he's been the Director of X4 Pharmaceuticals since 2018. There are 12 older and 2 younger executives at X4 Pharmaceuticals. The oldest executive at X4 Pharmaceuticals, Inc. is Dr. Robert David Arbeit, 73, who is the Sr. VP of Clinical Devel. and Translational Research.

What's Rene Russo's mailing address?

Rene's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134.

Insiders trading at X4 Pharmaceuticals

Over the last 6 years, insiders at X4 Pharmaceuticals have traded over $2,179,690 worth of X4 Pharmaceuticals stock and bought 25,000 units worth $30,000 . The most active insiders traders include Paula Ragan, Adam S. Mostafa y Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of $12,232. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth $1,744.

What does X4 Pharmaceuticals do?

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals executives and stock owners

X4 Pharmaceuticals executives and other stock owners filed with the SEC include:

• Paula Ragan,
  President, Chief Executive Officer, Corporate Secretary, Director
• Adam Mostafa,
  Chief Financial Officer, Treasurer
• Dr. Paula Ragan Ph.D.,
  Founder, CEO, Pres, Sec. & Director
• Derek M. Meisner Esq., J.D.,
  Chief Legal Officer & Corp. Sec.
• Adam S. Mostafa,
  CFO, Treasurer & Assistant Sec.
• Michael Wyzga,
  Independent Chairman of the Board
• Gary Bridger,
  Independent Director
• Murray Stewart,
  Independent Director
• David McGirr,
  Independent Director
• William Aliski,
  Independent Director
• Rene Russo,
  Director
• Candice Ellis,
  Director, Corporate Communications & Investor Relations
• Alison Lawton,
  Director
• Derek Meisner,
  General Counsel
• Arthur Taveras,
  Chief Scientific Officer
• Dr. Diego Cadavid M.D.,
  Chief Medical Officer
• Carrie Melvin M.B.A.,
  Sr. VP of Devel. Operations
• Dr. Robert David Arbeit,
  Sr. VP of Clinical Devel. and Translational Research
• Ronny Mosston M.B.A.,
  Sr. VP of HR
• Dr. Mary DiBiase Ph.D.,
  Chief Operating Officer
• Keith Woods,
  Director
• Craecker Francoise De,
  Director
• Christophe Arbet Engels,
  Chief Medical Officer
• Renato Skerlj,
  Chief Scientific Officer
• Lynne E Kelley,
  Chief Medical Officer
• Diego Cadavid,
  Chief Medical Officer
• Mary Di Biase,
  Chief Operating Officer